Your browser doesn't support javascript.
loading
Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy.
Shimomura, Akihiko; Yonemori, Kan; Yoshida, Masayuki; Yoshida, Teruhiko; Yasojima, Hiroyuki; Masuda, Norikazu; Aogi, Kenjiro; Takahashi, Masato; Naito, Yoichi; Shimizu, Satoru; Nakamura, Rikiya; Hamada, Akinobu; Michimae, Hirofumi; Hashimoto, Jun; Yamamoto, Harukaze; Kawachi, Asuka; Shimizu, Chikako; Fujiwara, Yasuhiro; Tamura, Kenji.
Afiliación
  • Shimomura A; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. Electronic address: ashimomu@ncc.go.jp.
  • Yonemori K; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Yoshida M; Department of Pathology, National Cancer Center Hospital, Tokyo, Japan.
  • Yoshida T; Department of Genetic Medicine, National Cancer Center Hospital, Tokyo, Japan.
  • Yasojima H; Department of Breast Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan.
  • Masuda N; Department of Breast Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan.
  • Aogi K; Department of Breast Surgery, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
  • Takahashi M; Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.
  • Naito Y; Department of Breast and Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Shimizu S; Department of Breast and Endocrine Surgery, Kanagawa, Cancer Center, Yokohama, Japan.
  • Nakamura R; Department of Breast Surgery, Chiba, Cancer Center, Chiba, Japan.
  • Hamada A; Department of Molecular Pharmacology, National Cancer Center Research Institute, Tokyo, Japan.
  • Michimae H; Department of Biostatistics, Kitasato University School of Pharmacy, Tokyo, Japan.
  • Hashimoto J; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan; Department of Medical Oncology, St. Luke's International Hospital, Tokyo, Japan.
  • Yamamoto H; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan; Department of Medical Oncology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.
  • Kawachi A; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Shimizu C; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan; Department of Breast Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan.
  • Fujiwara Y; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Tamura K; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Transl Oncol ; 12(10): 1386-1394, 2019 Oct.
Article en En | MEDLINE | ID: mdl-31382135
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Transl Oncol Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Transl Oncol Año: 2019 Tipo del documento: Article